Amryt Pharma PLC

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland.

Amryt Pharma plc - Key Dates for AIM Delisting

Key Dates for AIM Delisting

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT) has been boosted by positive trial results published by Lancet Diabetes & Endocrinology. The company, in a statement, told investors that the full results of The global Phase 3 MPOWERED clinical trial compared Mycapssa, oral octreotide capsules, to long-acting injectable Somatostatin Receptor Ligands (iSRLs) for maintenance of biochemical response in patients with acromegaly.

Amryt Pharma: full Phase 3 trial results published by Lancet

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa ® (oral octreotide) in Acromegaly P atients

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT) said its forecasts for 2021 revenues would be unaffected after the US Food and Drug Administration made a three-month extension to the review period for the new drug application (NDA) for its Oleogel-S10 for the treatment of junctional and dystrophic epidermolysis bullosa. This is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.

Amryt Pharma drug application review with FDA extended three months

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.

Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM

Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q3 2021 Results - Earnings Call Transcript

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 66.67% and 7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT) announced revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%. Revenue rose to US$56.5mln in the three months to end-September from US$49.3mln in the same period last year.

Amryt Pharma third-quarter revenue up over 14% on soaring metreleptin sales

Amryt Reports Strong Q3 2021 Results

Amryt Pharma PLC Sponsored ADR (AMYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Amryt Pharma PLC Sponsored ADR (AMYT) Q3 Earnings Expected to Decline

Amryt Pharma PLC has announced its support for Global Epidermolysis Bullosa (EB) Awareness Week, which is taking place October 25 - 31, 2021. Joe Wiley, Amryt's chief executive, said: "Epidermolysis Bullosa is a very distressing condition which severely impacts the lives of those living with EB and also has a profound impact on parents, families and all those involved in their care.

Amryt Pharma backs EB awareness week

A mryt to Report Q 3 202 1 Results and Host Conference Call & Webcast on November 3

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3

What the company does Amryt Pharma PLC (LON:AMYT) sells and develops orphan drugs used to treat rare diseases with two products on the market. Last year, Amryt acquired US group Aegerion Pharmaceuticals out of Chapter 11 bankruptcy protection in a transaction backed by convertible bondholders, creditors and Nasdaq-listed Novelion Therapeutics, Aegerion's parent company.

Amryt Pharma advancing on multiple fronts

Amryt has extended the patents on its lead development candidate, Oleogel-S10 and its recently acquired commercial product, Mycapssa. For Oleogel-S10, a treatment for skin condition EB, the US patent office has issued a new formulation patent to Amryt, which will be listable in the Approved Drug Products or  “Orange Book”.

Amryt Pharma extends patent protection on key products

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

Amryt Pharma has had its price target of US$40 and 'buy' rating reiterated by Canaccord after the company hosted a virtual capital markets day. Opinion leaders spoke on the near-term growth opportunities with Filsuvez in epidermolysis bullosa (EB) and Mycapssa in acromegaly, said the broker, which has underlined its optimistic view.

Amryt Pharma impresses broker at Capital Markets Day

Amryt Pharma has raised its full-year 2021 revenue guidance due to a strong performance from recent acquisition of Chiasma and its own commercial products. Revenues are now expected in a range of US220mln - $225mln compared to previous guidance of US$210mln- $215mln.

Amryt Pharma raises sales forecast again as acquisition makes strong start

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

Amryt Pharma (AMYT) CEO Dr. Joe Wiley on Q2 2021 Results - Earnings Call Transcript

Amryt Pharma PLC has raised its full-year guidance after the biopharmaceutical company delivered a record set of results in its second quarter. In its results for the quarter ended June 30, the company reported an operating profit before finance expense of US$4.1mln, swinging from a US$12mln loss a year ago, while revenues surged 35.9% to US$62.8mln.

Amryt Pharma ups guidance after record second quarter

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Chiasma

Amryt Pharma PLC has completed its acquisition of US group Chiasma Inc with Raj Kannan and Roni Mamluk joining the board as non-executive directors. Joe Wiley, Amryt's chief executive, said:  “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.

News for Amryt Pharma PLC Stock (AMYT)